Soleus Capital Management LP has recently announced that it has increased stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 33.82%. After grabbing 9.85 million shares, the institutional investor is now in possession of 2.49 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.51% having worth around $20.2 million. Moreover, AQR Capital Management LLC increased its share by 0.36 million to have a control over 2.55 million shares. And Citadel Advisors LLC raised its holdings to 1.28 million shares by acquiring 1.65 million shares or 1.26% of the stake.
Organogenesis Holdings Inc. (ORGO) concluded trading on 05/24/23 at a closing price of $3.99, with 2.87 million shares of worth about $11.45 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 53.46% during that period and on Wednesday the price saw a gain of about 15.99%. Currently the company’s common shares owned by public are about 131.08M shares, out of which, 64.70M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the ORGO stock and their offered price forecasts bring an average price target of $10.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $10.00 and could fall to a lowest price of $10.00. However, touching the estimated high of $10.00 would mean a gain of 60.1% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 58 times over the past 12 months. They bought 3,608,718 shares in 25 of the transactions. In 33 selling transactions, insiders dumped 900,613 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Federated Hermes MDT Small Cap Co are the top 3 mutual funds which are holding stakes in Organogenesis Holdings Inc. Vanguard Total Stock Market ETF is currently holding 1.88 million shares of worth totaling $3.86 million. The company recently came buying 0.0 shares which brought its stake up to 1.44% of the company’s outstanding shares. iShares Russell 2000 ETF sold 21680.0 shares, after which its hold over company’s outstanding shares shrunk to 1.13%, leaving 1.48 million shares with the mutual fund that have a worth of about $3.04 million. Federated Hermes MDT Small Cap Co, after selling 1.19 million shares, have now control over 0.91% of the stake in the company. It holds -0.52 million shares of worth $2.43 million.
Organogenesis Holdings Inc. (NASDAQ: ORGO) started trading at $3.96, above $0.52 from concluding price of the previous day. However, the stock later moved at a day high price of 4.1650, or with a gain of 15.99%. Stock saw a price change of 25.47% in past 5 days and over the past one month there was a price change of 103.57%. Year-to-date (YTD), ORGO shares are showing a performance of 48.33% which decreased to -30.61% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.79 but also hit the highest price of $6.52 during that period. The average intraday trading volume for Organogenesis Holdings Inc. shares is 1.51 million. The stock is currently trading 56.41% above its 20-day simple moving average (SMA20), while that difference is up 77.15% for SMA50 and it goes to 39.00% higher than SMA200.
Soleus Capital Management LP acquired 9.85 million shares of Organogenesis Holdings Inc. having value of about $20.2 million. Data submitted at the U.S SEC by Soleus Capital Management LP revealed that the firm now holds 2.49 million shares in the company valued at close to $9935100.0, or have control over 33.82% stake in the company. Organogenesis Holdings Inc. (NASDAQ: ORGO) currently have 131.08M outstanding shares and institutions hold larger chunk of about 43.20% of that. Holding of mutual funds in the company is about 28.99% while other institutional holders and individual stake holders have control over 60.66% and 12.31% of the stake respectively.
The stock has a current market capitalization of $505.73M and its 3Y-monthly beta is at 1.27. PE ratio of stock for trailing 12 months is 39.12, while it has posted earnings per share of $0.10 in the same period. Its PEG reads 16.23 and has Quick Ratio of 2.50 while making debt-to-equity ratio of 0.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ORGO, volatility over the week remained 8.85% while standing at 9.24% over the month.
Analysts are in expectations that Organogenesis Holdings Inc. (ORGO) stock would likely to be making an EPS of $0.03 in the current quarter, while forecast for next quarter EPS is $0.02 and it is $0.28 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.03 which is $0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.07 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -83.50% while it is estimated to increase by 340.00% in next year. EPS is likely to shrink at an annualized rate of 2.41% for next 5-years, compared to annual growth of 17.60% made by the stock over the past 5-years.
Analysts at 1 brokerage firms have issued recommendations for the Organogenesis Holdings Inc. (ORGO)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Leave a Reply